Piramal Healthcare Chairman Ajay Piramal On Meeting The World's Need For High Quality Delivered At Low Cost: An Interview With PharmAsia News (Part 2 of 2)
This article was originally published in PharmAsia News
Executive Summary
Ajay Piramal, chairman of the $550 million Piramal Healthcare and Piramal Lifesciences, recently sat down with PharmAsia News' India Bureau to talk about the role India plays in the global market and to share his vision for the company.
You may also be interested in...
Piramal Deal Done, Abbott's India Plunge May Fetch Big Returns, But Integration Challenges, Growth Momentum Critical
MUMBAI - Piramal Healthcare Chairman Ajay Piramal redefined the valuation processes for Indian life science companies last week, when he sold his domestic business of predominantly 350 branded generic products to Illinois-based Abbott for $3.72 billion - a jaw-dropping price that is nine times the level of annual sales and 31 times that of earnings
Piramal Deal Done, Abbott's India Plunge May Fetch Big Returns, But Integration Challenges, Growth Momentum Critical
MUMBAI - Piramal Healthcare Chairman Ajay Piramal redefined the valuation processes for Indian life science companies last week, when he sold his domestic business of predominantly 350 branded generic products to Illinois-based Abbott for $3.72 billion - a jaw-dropping price that is nine times the level of annual sales and 31 times that of earnings
"With A Molecule That Is A Million Times Larger Than A Small Molecule, So Many Things Can Go Wrong," Says Biogen Idec Asia Operations Head Gunther Winkler
Gunther Winkler, Biogen Idec's Senior Vice President, International Business, is responsible for expanding the company's Asia operations. Winkler, a close watcher of biosimilars regulations being adapted by various countries, is skeptical about the safety of copied biotech drugs and therefore calls for sufficient caution on the approval mechanism for such drugs. In an interview with PharmAsia News' India bureau, Gunther Winkler spells out the company's ambitions in Asia, which includes research on products that could be relevant to local populations.